RT Journal Article
SR Electronic
T1 Role of Nuclear Receptors in Lipid Dysfunction and Obesity-Related Diseases
JF Drug Metabolism and Disposition
JO Drug Metab Dispos
FD American Society for Pharmacology and Experimental Therapeutics
SP 1
OP 11
DO 10.1124/dmd.112.048694
VO 41
IS 1
A1 Hollie I. Swanson
A1 Taira Wada
A1 Wen Xie
A1 Barbara Renga
A1 Angela Zampella
A1 Eleonora Distrutti
A1 Stefano Fiorucci
A1 Bo Kong
A1 Ann M. Thomas
A1 Grace L. Guo
A1 Ramesh Narayanan
A1 Muralimohan Yepuru
A1 James T. Dalton
A1 John Y. L. Chiang
YR 2013
UL http://dmd.aspetjournals.org/content/41/1/1.abstract
AB This article is a report on a symposium sponsored by the American Society for Pharmacology and Experimental Therapeutics and held at the Experimental Biology 12 meeting in San Diego, CA. The presentations discussed the roles of a number of nuclear receptors in regulating glucose and lipid homeostasis, the pathophysiology of obesity-related disease states, and the promise associated with targeting their activities to treat these diseases. While many of these receptors (in particular, constitutive androstane receptor and pregnane X receptor) and their target enzymes have been thought of as regulators of drug and xenobiotic metabolism, this symposium highlighted the advances made in our understanding of the endogenous functions of these receptors. Similarly, as we gain a better understanding of the mechanisms underlying bile acid signaling pathways in the regulation of body weight and glucose homeostasis, we see the importance of using complementary approaches to elucidate this fascinating network of pathways. The observation that some receptors, like the farnesoid X receptor, can function in a tissue-specific manner via well defined mechanisms has important clinical implications, particularly in the treatment of liver diseases. Finally, the novel findings that agents that selectively activate estrogen receptor β can effectively inhibit weight gain in a high-fat diet model of obesity identifies a new role for this member of the steroid superfamily. Taken together, the significant findings reported during this symposium illustrate the promise associated with targeting a number of nuclear receptors for the development of new therapies to treat obesity and other metabolic disorders.